The objective of this study was to evaluate whether extracorporeal magnetic innervation (ExMI) combined with a-blocker therapy is more effective than a-blocker monotherapy for patients with non-inflammatory chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), category IIIB. Patients were randomized to either terazosin monotherapy (group 1, n ¼ 21) or terazosin combined with ExMI therapy (group 2, n ¼ 19). Patients in group 2 had 12 treatment sessions of ExMI twice a week during 6 weeks. None of the patients experienced any side effects from treatment. The changes in each domain of the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) measured on week 6 were not significantly different between the groups. However, the difference (median, 25-75th percentiles) between the two groups in total NIH-CPSI scores was À4 (À11.5, À2) for group 1 and À12 (À17.3, À2.3) for group 2, respectively (P ¼ 0.047). At 6 weeks, 47.6% (10 of 21) of group 1 had a 425% decrease in total NIH-CPSI compared with 78.9% (15 of 19) of group 2 (P ¼ 0.041). Also, more patients in group 2 (78.9%) were rated as responders with a 6-point decrease in NIH-CPSI compared with group 1 (47.6%) (P ¼ 0.041). The early results suggest that ExMI combined with a-blocker therapy has better effect than a-blocker monotherapy for the treatment of CP/CPPS.
Introduction
Chronic prostatitis(CP)/chronic pelvic pain syndrome (CPSS) is a common disease and an important urologic problem in adult men of all ages. This constellation of symptoms would suggest that an infection in the prostate gland is present, but the pathological basis for CP/CPPS has not yet been defined, as the presence of an infectious agent can be demonstrated in only 5-10% of patients with symptoms suggestive of CP/CPPS. 1, 2 However, despite evidence indicating that only 5-10% of symptomatic men have positive cultures localized to the prostate gland, most physicians continue to prescribe antibiotics for this condition.
McNaughton Collins et al. 3 examined all published randomized or controlled trials for the treatment of nonbacterial CP/CPPS in a systematic review. They concluded that no treatment approach was currently supported by the available evidence. The recent study by the Chronic Prostatitis Collaborative Research Network 4 demonstrated that ciprofloxacin and tamsulosin were not effective treatments for long-standing, refractory CP/CPPS. Because evidence for the effectiveness of antimicrobial therapy is lacking in the vast overbalance of CP/CPPS cases, the practice of empirical antimicrobial therapy for most men with CP/CPPS should be reexamined. In addition, as the clinical effect of a-blocker was modest, it cannot be recommended as a monotherapy. [5] [6] [7] Magnetic stimulation has been developed for the noninvasive stimulation of the central and peripheral nervous system. 8 It is the nerves that are most sensitive to electrical depolarization by a changing magnetic field. When the nerve is a motor nerve, depolarization will cause a propagating impulse that will release neurotransmitters at the motor end plates and provoke muscle contraction. 9 Thus, initial investigations of clinical applications for extracorporeal magnetic innervation (ExMI) of the pelvic floor have focused on the treatment of stress urinary incontinence. However, Rowe et al. 10 suggested that the use of electromagnetic therapy might be a promising non-invasive option for CP/CPPS. We hypothesized that depolarization can also occur in sensory afferent fibers and autonomic nerves that may regulate local blood flow and other factors. The present study was designed to evaluate whether ExMI combined with a-blocker therapy is more effective than a-blocker monotherapy for patients with non-inflammatory CP/ CPPS, category IIIB.
Materials and methods

Participants
From December 2003 to July 2004, 40 men with a clinical diagnosis of CP/CPPS IIIB were prospectively studied. Before their inclusion in the study, all patients gave their informed consent. The study inclusion criteria were as follows: age of at least 18 years, pelvic pain defined as pain in the bladder, groin, genitals or lower abdomen and/or perineal or (peri)anal areas without clear abnormalities on urological examination, and the ability to communicate, understand and comply with the requirements of the study. The exclusion criteria of this study included symptoms for less than 6 months, acute or chronic urethritis, urinary stones, bacterial or inflammatory CP/CPPS, bladder cancer, prostate cancer, urethral strictures, neurogenic bladder dysfunction, restricted mobility and antimicrobial or anti-inflammatory medication up to 4 weeks before enrollment in our study. Patients were also excluded from the analysis if they had a documented history of prostatic intraepithelial neoplasia on biopsy, serum prostate-specific antigen levels in excess of 20 ng/ml, history of prostate surgery or radiotherapy and acute urinary retention or an indwelling catheter. Patient characteristics are given in Table 1 .
Study design
Patients were evaluated, including a detailed medical history, physical examination, serum prostate-specific antigen, transrectal ultrasonography, uroflowmetry, postvoiding residual (PVR) urine volume measurement using bladder scans (BVI-3000, Diagnostic Ultrasound Co., Redmond, WA, USA) and symptom score evaluation using the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) 11 and the International Prostate Symptom Score (I-PSS). 12 First voided urine, midstream urine, expressed prostatic secretions and urine after massage as well as ejaculate were microscopically examined and cultured. The definition of CP/ CPPS criteria confirmed to the guidelines from the first NIH International Prostatitis Collaboration Network reports. 13 Patients were randomized according to the closed-envelop method at a 1:1 ratio to either terazosin monotherapy (group 1, n ¼ 21) or terazosin combined with ExMI therapy (group 2, n ¼ 19).
Method of treatment
All patients in groups 1 and 2 were administered 2 mg terazosin once per day for the first 7 days, and continued to receive 4 mg of terazosin once daily for the following 5 weeks. For ExMI, the Neoconrol system (Neotonus Inc., Marietta, GA, USA) was used. Within the chair's seat is a magnetic field generator (therapy head) that is powered and controlled by an external power unit. The output of the power unit consists of pulses of current 275 min in duration, which can be adjusted in amplitude by the clinician. Adjusting this amplitude determines the size ExMI and terazosin for CPPS IIIb J-S Paick et al and strength of the magnetic field. The leading edge of these pulses is quite steep, creating a steep gradient magnetic field that is concentrated and directed vertically through the seat of the chair. When the patient is seated, the perineum is centered naturally in the middle of the seat, which places the muscles of the pelvic floor and sphincters directly on the primary axis of the pulsing magnetic field. This allows all the tissues of the perineum to be penetrated by the therapeutic magnetic field flux.
14 Treatment sessions were for 20 min, twice a week for 6 weeks. The frequency of the pulse field was 10 Hz, intermittently for 10 min, followed by a rest period of 2 min, and a second treatment at 50 Hz intermittently for 10 min. The magnetic coil was set on an armchair-type seat, and the patients were instructed to sit so that they would feel the highest contraction of the anal sphincter during the stimulation. The stimulating intensity was gradually increased up to the tolerable limit.
Evaluation of results
The NIH-CPSI determined before and after treatment. The Korean version of the NIH-CPSI used in the study has been validated in Korea. 15 The NIH-CPSI had four questions regarding pain, two regarding urinary symptoms and three regarding quality of life (QOL). The questions regarding pain included location (items 1 and 2), frequency (item 3) as well as severity (item 4) of pain, and those regarding urinary symptoms included incomplete emptying (item 5) and frequency of urination (item 6). This index also includes impact questions for measuring the limitations of activities and psychological distress (items 7 and 8) and the final section questions overall QOL (item 9). The I-PSS, maximum flow rate (Qmax) and PVR urine volume were also analyzed because patients with CP/CPPS often experience urinary symptoms that terazosin might ameliorate.
Statistical analysis
Survey responses were coded and analyzed with descriptive statistics. All values are expressed as median (25-75th percentiles) or number (%). The medians of each domain across two groups were compared using the Mann-Whitney U-test. Categorical variables were compared using the Armitage test. The Wilcoxon signed-rank test was used to compare the values before and after treatment in each group. The primary outcome parameter was the change in the overall NIH-CPSI score from baseline to 6 weeks. The three domain scores of the NIH-CPSI and the responder analyses were treated as secondary outcome parameters. NIH-CPSI responders were defined as patients who had experienced a 25% and/or a 6-point decrease (6-point responders) in the total NIH-CPSI score from the baseline values. 16, 17 A 5% level of significance was used for all statistical testing, and the statistical analyses were performed using a commercially available analysis program, SPSS (SPSS Inc., Chicago, IL, USA).
Results
There were no serious side effects in both groups. At baseline, no differences were evident in the two groups with the NIH-CPSI and I-PSS as well as Qmax and PVR except impact on QOL domain of the NIH-CPSI (P ¼ 0.022). Six weeks after treatment, the scores of the NIH-CPSI and the I-PSS as well as Qmax and PVR were not significantly different in the two groups. The values of Qmax and PVR did not change with treatment, but remained at a similar level in both groups. The baseline and post-treatment clinical parameters in each group are shown in Table 2 .
The changes in each domain of the NIH-CPSI measured on week 6 were not significantly different between the groups. In contrast, the difference between the two groups in total NIH-CPSI scores was À4 (À11.5, À2) for group 1 and À12 (À17.3, À2.3) for group 2, respectively (P ¼ 0.047). When the I-PSS score was compared, the change of total score was greater than in group 2 than in group 1 (P ¼ 0.026), although we did not note a statistical significance in the decrease of QOL index (Table 3) .
At 6 weeks, 47.6% (10 of 21) of group 1 had a 425% decrease in total NIH-CPSI (defined as a responder) compared with 78.9% (15 of 19) of group 2 (P ¼ 0.041). Also, more patients (78.9%) in group 2 were rated as responders with a 6-point decrease in NIH-CPSI compared with group 1 (47.6%) (P ¼ 0.041).
Discussion
CP/CPPS is a clinical syndrome characterized by pain in the perineum, pelvis, suprapubic area, or external genitalia and variable degrees of voiding and ejaculatory disturbance. 18 Men with CP/CPPS experience healthrelated QOL impairment. 19, 20 Patients tend to miss some work and experience some degree of depression, with 5% admitting to thoughts of suicide owing to their symptoms. 21 The QOL of a patient with CP/CPPS is similar to that of a patient with recent myocardial infarction, unstable angina or Crohn's disease. 20 Turner et al., 22 examining men in primary-care settings for QOL, reported that worse QOL was associated with greater pain and urinary symptoms and that pain was more robustly associated with worse QOL than were urinary symptoms. Recently, Tripp et al. 23 also reported that pain intensity and urinary symptoms were independent predictors of QOL, with pain intensity the strongest predictor. The hallmark of CP/CPPS is its symptom complex, and, therefore, controlling the symptom profile is an integral part of managing this complex condition.
In recent years, magnetic stimulation has been investigated as an alternative to electrical stimulation. It is based on a principle of physics, that a changing magnetic field will induce a flow if electrons within the field. The safety profiles of ExMI technology have been studied and the devices have been approved for clinical use; a review of safety issues has been published. 24 A magnetic field passes uninterrupted through clothing; thus, it is not necessary to undress for treatment. There are unique advantages to magnetic stimulation when it is necessary to stimulate nerve structures. A magnetic field penetrates all body tissues without significant alteration and the magnitude of the field falls off only as the inverse square of the distance. There is some evidence that magnetic stimulation of the sacral nerve roots may ExMI and terazosin for CPPS IIIb J-S Paick et al suppress detrusor overactivity. 25, 26 It therefore seems reasonable to assume that magnetic stimulation acts on pudendal afferents in the same way as intravaginal electrical stimulation.
To date, there are no standard confirmed therapies indicated for treating CP/CPPS. Because this was a pilot investigation, the sample size was small. In our study, although the observed trend of the subscale scores was in favor of the combination therapy group, we observed no statistically significant difference in the two groups. In addition, we could not demonstrate a statistically significant difference on the QOL scores of each questionnaire for the two groups. The lack of statistically significant improvement may have been a result of the relatively small number of randomized patients. Finally, in the present study, one group was only treated with terazosin monotherapy whereas the other group received intensive contact and open treatment. This 'clinical effect' might lead to significant sham/placebo effect. Further studies are needed to clarify the effects of ExMI therapy for non-inflammatory CP/CPPS, using a larger number of patients in a randomized, placebo-controlled trial.
Conclusions
ExMI therapy offers a new approach for pelvic floor stimulation that improves CP/CPPS. A longer follow-up is required to determine how long the benefits of treatment will last and whether retreatment will be necessary. In addition, the next step in future research will be to determine possible mechanisms of action of ExMI and to identify factors influencing the outcomes. The early results suggest that ExMI combined with ablocker therapy may have better effect than a-blocker monotherapy for the treatment of CP/CPPS. ExMI and terazosin for CPPS IIIb J-S Paick et al
